DrugPatentWatch Database Preview
Drugs in Development Information for DEBIO-1347
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug DEBIO-1347?
DEBIO-1347 is an investigational drug.
There have been 20 clinical trials for DEBIO-1347.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2015.
The most common disease conditions in clinical trials are Bacterial Infections, Hepatitis, Chronic, and Hepatitis C, Chronic. The leading clinical trial sponsors are Debiopharm International SA, Centre Leon Berard, and Merck Sharp & Dohme Corp.
Summary for DEBIO-1347
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 5 |
| WIPO Patent Applications | 1 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2015-05-01) |
| Vendors | 35 |
Recent Clinical Trials for DEBIO-1347
| Title | Sponsor | Phase |
|---|---|---|
| Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors | Debiopharm International SA | Phase 1 |
| Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143 | Debiopharm International SA | Phase 1/Phase 2 |
| Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma | Debiopharm International SA | Phase 1 |
Clinical Trial Summary for DEBIO-1347
Top disease conditions for DEBIO-1347
Top clinical trial sponsors for DEBIO-1347
US Patents for DEBIO-1347
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
